Vivienne Taylor, MD
Internal Medicine · Rome, NYNPI 1861464372
Payments from drug & device makers
Across 58 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$223
- Pfizer$161
- Madrigal Pharmaceuticals$108
- Novo Nordisk$74
- AstraZeneca$67
- Gilead$62
- plus $497 from 15 others
What the payments were for
- Food & beverage$1,17999%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $223 |
| Pfizer | 8 | $161 |
| Madrigal Pharmaceuticals | 3 | $108 |
| Novo Nordisk | 4 | $74 |
| AstraZeneca | 4 | $67 |
| Gilead | 3 | $62 |
| Indivior Inc. | 3 | $52 |
| Exact Sciences | 3 | $52 |
| Merck | 3 | $48 |
| Dexcom, Inc. | 2 | $48 |
| AbbVie | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Amgen | 1 | $20 |
| Grifols USA, LLC | 1 | $20 |
| Vertex | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$120
How this compares
$1,193 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $114,599 |
| JardianceEmpagliflozin | 51 | $89,966 |
| XareltoRivaroxaban | 24 | $39,221 |
| JanuviaSitagliptin Phosphate | 37 | $34,168 |
| TradjentaLinagliptin | 23 | $31,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $28,922 |
| OxycontinOxycodone Hcl | 24 | $24,189 |
| FarxigaDapagliflozin Propanediol | 14 | $19,263 |
| MounjaroTirzepatide | 16 | $18,546 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $15,354 |
| EliquisApixaban | 11 | $14,155 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $10,414 |
| VascepaIcosapent Ethyl | 11 | $8,383 |
| Pregabalin | 134 | $4,908 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $4,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $74 | $114,599107 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $223 | $44,27675 claims |
| MerckJanuvia | $48 | $34,16837 claims |
| AstraZenecaFarxiga | $67 | $19,26314 claims |
| Lilly USA, LLCMounjaro | $41 | $18,54616 claims |
| PfizerEliquis | $161 | $14,15511 claims |
| Indivior Inc.Suboxone | $52 | $3,69012 claims |
| AbbVieSynthroid | $44 | $2,18628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Rome
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.